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Summary The tritium-labelled analogues of pimonidazole and RSU 1069 were injected into mice bearing the
KHT murine sarcoma which has a hypoxic cell fraction of 1-0%. The distribution of activity at 24 h was
recorded using autoradiography and measurement of tissue activity. Autoradiographs with both drugs showed
high activity in particular cells within tumour, eye (melanin-associated cells), eyelid (Meibomian gland), liver
(centrilobular area), skin (sebaceous gland and melanin), stomach (squamous area), footpad, oesophagus,
labial gland, Zymbal's gland, preputial gland, parotid gland (intralobular ducts) and airway epithelium. These
tissues had previously been identified as sites of binding of misonidazole. The measurement of total tissue
radioactivity showed significantly higher activity in liver, eyelid (Meibomian gland), oesophageal lining, kidney
and labial gland than was found in the tumour.
Misonidazole (1-(2-nitro-1-imidazolyl)-3-methoxy-2-propan-
ol; MISO) sensitises hypoxic tumour cells to ionising radia-
tion (Asquith et al., 1974). This radiosensitisation is assoc-
iated with the electron affinity of,MISO and is a fast (sub-
second) free-radical process. MISO can also be involved in a
separate, slower, enzyme dependent process in which, in the
presence of the appropriate reductase(s), the nitro group is
reduced yielding cytotoxic species (Varghese et al., 1976;
Rauth, 1984). This second process is favoured by a hypoxic
environment - such as occurs in parts of many tumours -
and this leads to locally enhanced retention. The concept of
the preferential retention of reactive bioreduced metabolites
in tumours has generated two lines of research. One is
directed towards tumour therapy (bioreductive drug therapy).
In this, drugs are being developed which, as with MISO, on
reduction in the hypoxic milieu of the tumour, form cyto-
toxic metabolites(s) that bind to critical macromolecules such
as DNA. The other line of research is in the field of imaging
and spectroscopy. The parent compound is labelled with a
radionuclide (Rasey et al., 1987), or with an element suitable
for magnetic resonance imaging or MR spectroscopy (Ra-
leigh et al., 1986; Maxwell et al., 1989a). The imaging com-
pound is reduced and retained preferentially in the hypoxic
milieu of the tumour and is then visualised when the
differential between tumour and adjacent tissues is maximal.
In most instances it has not yet been possible to identify the
metabolite(s) responsible for cytotoxicity or imaging.
Preferential binding of MISO within tumours was first
illustrated by Chapman et al. (1981). Carbon-14-labelled
MISO was given to tumour-bearing mice which were killed
after 3 h and autoradiographs (ARG) of the tumours were
prepared. The ARGs showed a dense band of grains in the
area between the viable tumour and its necrotic centre. It was
assumed that this band of grains represented binding to
hypoxic cells in the tumour. Recently, while repeating this
work, we have observed similarly high levels of grain count
in a number of apparently normoxic normal tissues in mice.
These tissues are: those of sebaceous gland origin (Mei-
bomian gland, skin sebaceous gland, Zymbal's gland, labial
gland, vulval gland, perianal gland and preputial gland);
stratified squamous epithelia (oesophagus, squamous stom-
ach lining, footpad); lung (airway epithelium); liver and
enamel organ of the incisor (Cobb et al., 1989; Cobb &
Nolan, 1989). When many of these tissues are examined by
histochemistry they stain strongly for reductase activity
(Cobb et al., 1990a).
Because of the possible relevance of this high level of
binding in normal tissues to research in tumour visualisation
and bioreductive drug therapy we have extended this work
to examine two analogues of misonidazole to see if the
phenomenon is specific to MISO or can be observed more
widely. Pimonidazole (a-[(2-nitro-1-imidazolyl)methyl]-1-pip-
eridine-ethanol; RO 03-8799; PIMO) is a lipophilic MISO
analogue in which the methoxy group has been replaced by a
piperidine group (Smithen et al., 1980). It was thought that
being weakly basic it might assist in tumour retention and
produce a more rapid clearance in acid urine than the parent
MISO. The theory that the basic side-chain could lead to
improved concentration in the acidic milieu of tumours is
supported by the work of Dische et al. (1986a,b) and Roberts
et al. (1986) who have observed in patients a tumour concen-
tration of approximately twice that of MISO. This com-
pound has had a limited clinical trial (Saunders et al., 1984;
Roberts et al., 1986). RSU 1069 (1-(2-nitro-1-imidazolyl)-3-
(1-aziridinyl)-2-propanol) is a MISO analogue in which an
aziridine group replaces the methoxy group in the Nl side-
chain (Adams et al., 1984). It is thought to act as a
monofunctional alkylating agent (aziridine group) under nor-
moxic conditions and under hypoxic conditions as a bifunc-
tional alkylating group through the aziridine group and the
reduced nitro group (Stratford et al., 1986). As a hypoxic-cell
cytotoxin it is 100 times more toxic to anoxic than to nor-
moxic cells in vitro (Ahmed et al., 1986; Stratford et al.,
1986). In a limited clinical trial it has been found to cause the
side-effects of nausea and vomiting (Horwich et al., 1986).
In the present study we have recorded the distribution of
3H-PIMO and 3H-RSU 1069 in the tissues of tumour-bearing
mice by whole organ measurement of the tritium, and by
ARGs of the tissues.
Materials and methods
The ten animals used were male C3H/He mice aged 11-13
weeks. Their pathogen-free status was maintained by the use
of positive pressure isolators. The mice had a subcutaneous
KHT sarcoma growing on the rump. At the size of tumour
used in the present study (6 mm diameter) the radiobiologi-
cally hypoxic cell fraction has been calculated as 10% (Strat-
ford et al., 1989).
Both PIMO and RSU 1069 were labelled with tritium on
the two carbon of the side-chain (Webb & Threadgill, 1990).
The relative specific activities were 18 and 17 MBq mg '
respectively. For each drug five mice were injected i.v. with a
single injection in PBS (pH 7.4); 50 mg kg-' for PIMO and
40mg kg-' for RSU 1069. The i.v. LD,o/7d of cold PIMO
and RSU 1069 are 580 and 160 mg per kg body weight
respectively.
After 24 h all animals were killed by i.p. sodium bar-
biturate and samples ofthe following tissues taken from each
animal and weighed: eyelids (--d20% of which is Meibomian
gland), Zymbal's gland (ear canal: Pohl & Fouts, 1983),
preputial gland, liver, oesophageal epithelium, footpads,
KHT tumour, lung, muscle (quadriceps), kidney, brain (one
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whole side), spleen, parotid salivary gland, blood, labial
gland (lingual surface of cheek). The labial gland is an ag-
gregation of sebaceous glands associated with the hairs in the
labial vestibule (Quay, 1965).
Tritiated water was removed from the tissue samples by
three cycles of dehydration with ethanol (overnight in the
first instance and subsequently for a minimum of 4 h) and
rehydration with distilled water. It was expected that this
would remove tritiated water and some small water-soluble
molecules (Franko et al., 1989). Blood was similarly dehy-
drated using three cycles of drying/rehydration in vacuo over
P205. The samples were then prepared for liquid scintillation
counting by dissolution in 1.0 ml of OptiSolve (LKB Scintil-
lation Products (Pharmacia), Milton Keynes, UK) at 55°C
for 16 h. Fifteen ml of OptiPhase (LKB Scintillation Pro-
ducts (Pharmacia), Milton Keynes, UK) was added and the
samples counted on a Beckmann LS 5000 CE liquid scintilla-
tion counter (Beckman Instruments Inc., Fullerton, CA,
USA) using the external standard generated H number to
estimate the counting efficiency.
The following tissues were taken for ARG: eyelids, eyeball,
labial gland, Zymbal's gland, preputial gland, KHT tumour,
lung (to include bronchi), liver, oesophagus, muscle (quad-
riceps), kidney, stomach (squamous and glandular), brain
(sagittal section), footpads, spleen, parotid gland and rostral
part of the nasal passages. The tissues were processed to
3-5 ltm paraffin sections and dipped in K2 emulsion (Ilford
Emulsion, Knutsford, Cheshire, UK) for ARG. Exposure
periods of from I to 14 weeks were used. The ARGs were
developed, stained with haematoxylin and eosin, and exam-
ined microscopically to identify the distribution and density
of grains in the emulsion overlying the tissue.
Results
Tissue distribution studies
The following results expressed as per cent injected tritium
per g wet weight are multiplied by 100 for ease of presenta-
tion. For PIMO and RSU 1069 respectively the values
( ± s.d.) were: KHT tumour 7.8 (0.9), 33.0 (13.0); blood 1.2
(0.6), 33.6 (4.7); footpads 4.3 (1.1), 40.5 (4.1); parotid gland
3.2 (0.8), 21.6 (5.5); eyelid 20.5 (3.9), 171.9 (42.7); Zymbal's
gland 3.6 (0.8), 22.8 (2.6); labial gland 5.5 (1.1), 62.8 (15.4);
brain 1.3 (0.3), 18.5 (1.4); preputial gland 6.8 (2.9), 27.7
(11.8); liver 20.0 (5.4), 115.1 (25.1); spleen 3.5 (2.2), 43.3
(5.9); kidney 6.5 (1.4), 88.2 (9.9); oesophageal epithelium 34.2
(1.4), 99.4 (35.6); lung 3.1 (1.1), 32.2 (1.1); muscle 1.7 (0.3),
34.9 (3.5). The tissue measurements were then expressed as a
ratio to the KHT tumour value and subjected to statistical
analysis. All significant values together with a number of
non-significant background tissue values are given in Table I.
Table I Activity in various tissues 24 h after injection, expressed as a
ratio to the tumour value
RSU 1069 PIMO MISOa
Liver 3.5 (0.72) *** 2.6 (0.34) * 3.5 (0.41) ***
Meibomian glandb 5.2 (1.12) * 2.6 (0.26) * 1.3 (0.47) *
Oesophageal 3.1 (0.73) *** 4.37 (0.83) *** 9.8 (0.80) *
epithelium
Kidney 2.7 (0.51) ** 0.83 (0.12) 1.2 (0.35)
Labial gland 1.9 (0.41) * 0.71 (0.07) n.a.
Blood 1.0 (0.20) 0.16 (0.03) 0.49 (0.30)
Muscle 1.1 (0.20) 0.22 (0.02) 0.38 (0.08)
Spleen 1.3 (0.25) 0.45 (0.13) 0.40 (0.10)
aValues from Cobb et al. (1990b). These values are for '4C-labelled
MISOinjected into micebearing theA 110mouselungtumour. n.a., not
available; bThe eyelids, of which -20% is Meibomian gland, were
removed and theactivitymeasured. ARGsshowed that the Meibomian
gland held much the greater part ofthe retained activity. The statistical
significance ofthe tissue levels above tumour level was calculatedusing
the Mann-Whitney test. *P<0.05; **P<0.01; ***P<0.00. Each
compound had been injected into a group of five mice. s.d. in
parentheses.
Also in this table are measurements taken from a previous
publication on MISO (Cobb et al., 1990b).
Autoradiography
With the exception of cells of macrophage lineage and
melanin-containing cells (see below) the tissues at 24 h with
noticeably high grain counts in PIMO- and RSU 1069-
injected mice were the same as those in which high levels of
MISO had previously been observed and measured (Cobb et
al., 1989; Cobb & Nolan, 1989). They fell into five distinct
tissues or groups of tissues.
1. Sebaceous gland group. This group comprised the se-
baceous gland of the hair follicles, the Meibomian gland of
the eyelids, Zymbal's gland of the ear canal, the labial gland
on the lingual surface of the cheek and the preputial gland.
These are histologically similar glands which all exhibit
holocrine secretion; that is, the entire mature cell is secreted.
Basal cells proliferate and a percentage mature to form the
glandular secretion. The maturation process involves a gross
enlargement of the cells by lipids, and nuclear degeneration.
The radioactivity at 24 h was observed to some extent over
the maturing cells and more so those in the process of
secretion through the duct(s) to the exterior.
2. Keratinised stratified squamous epithelial cell group.
This group comprised skin, oesophageal lining, the squamous
area of the stomach lining and the footpads. The grains were
concentrated over the stratum granulosum and the deeper
parts of the keratinised layer (Figure 1). The highest grain
density for both drugs (as for MISO) was in the oesophageal
lining. The grain count in the skin of the eyelids, nares and
footpads was patchy.
3. Lung. Activity was centred over the epithelium lining
the airways. The grain density was clearly less in this tissue
than in (1) and (2) above.
4. Liver. For both drugs, as for MISO, there was a high
grain density in the cells surrounding the centrilobular veins
(zone 3).
5. Parotid gland. As had previously been observed for
MISO, PIMO and RSU 1069 showed a higher grain count
over the epithelial cells lining the intralobular ducts than in
the surrounding tissues.
Figure I Junction of glandular with keratinised stratified squa-
mous area of stomach (ARG). The PIMO metabolite 24 h post-
injection is localised only in the squamous area, predominantly in
the upper cells of the stratum pigmentosum and the adjacent
lowest layers of the keratinised cells (arrow heads). One such area
is shown inset enlarged x 3.5. At the bottom of the inset are the
cells of the basal epithelium. They have a somewhat higher than
background grain count; as do the cells of the next layer (stratum
spinosum). The highest grain count is over the stratum granu-
losum and the first few layers of the keratinised cells. Thereafter
the count falls away rapidly at the top of the inset. The bar
represents 60 inm.PIMO AND RSU 1069 IN TISSUES 917
Figure 2 Area of heavily pigmented skin to show binding of
RSU 1069 to melanin (ARG). Twenty-four hours after the injec-
tion of 3H-RSU 1069 the ARG shows high activity over cells
which are known to contain melanin (arrows). In this illustration
only the grains in the ARG emulsion can be seen. The presence
of melanin granules beneath required examination at high
magnification when the black grains in the emulsion could be
seen separately from the underlying pale golden brown melanin
granules. The asterisk is in an area of heavy grain density over
melanocytes and melanin-impregnated epidermal cells in the
lower layers of the epidermis. The arrow head points to heavy
grain density above a pigmented hair. The bar represents 60 tm.
In addition to the above tissues, PIMO- and RSU 1069-
injected mice showed high grain density above melanin-
containing cells (Figure 2). This was particularly clear in the
skin of the eyelids and in the footpads. The melanin was in
both melanocytes and adjacent melanin impregnated epi-
thelial cells.
For RSU 1069 but not PIMO the macrophages in the liver
(Kupffer cells), spleen and skin (tissue histiocytes) were
associated with high grain density, indicative of the accumu-
lation within these cells of a labelled metabolite and there
was a high grain count over small cells in the brain which
had a scattered distribution similar to that of microglia (mac-
rophage lineage) (Merz et al., 1987).
Discussion
The main points arising from the results are that with the
two MISO analogues PIMO and RSU 1069 activity was
retained in much the same tissues as had previously been
observed for MISO; and that there was activity in some
normal tissues significantly in excess of the subcutaneous
tumour.
The tissue samples were dehydrated because there is good
evidence that the tritium associated with MISO tissue levels
at 24 h is to a significant extent due to tritiated water
(Franko et al., 1989; Cobb et al., 1990b). In the absence of
any other evidence we have concluded that the same might
apply to the two analogues of MISO and that with the
tritiated water removed we believed that the activity was
likely to be associated predominantly with bound metabolites
of the two drugs. This concept is supported by the close
correlation of high tritium retention with high grain count in
the target tissues: sebaceous gland group, stratified squamous
epithelium (oesophagus) and liver. In a recent publication on
MISO we have pointed out that these tissues have in com-
mon high levels of reductase and we have suggested that,
despite the likely presence of significant amounts of oxygen,
nitroimidazoles are reduced to reactive, binding, metabo-
lite(s) in these tissues (Cobb et al., 1990a). The same may
well apply to PIMO and RSU 1069.
The levels of radioactivity in the various tissues were
measured at only one point in time (24 h) and it is possible
that the ratio of one tissue level to another could change with
time. However, the ARG grain density, which would reflect
binding by reactive metabolites in the first few hours was
high in tissues showing high tissue to tumour ratios at 24 h
(Table I) thus indicating that the measurements of tissue
activity at 24 h were probably not anomalous.
The high level of MISO retained by the liver has frequently
been commented upon. Garrecht and Chapman (1983) in-
jected '4C-MISO into mice bearing the EMT-6 tumour and
reported high levels of adduct in liver and tumour as well as
lower levels in all normal tissues sampled. The two drugs in
the present report showed a similar high liver retention, with
preferential localisation in the centrilobular zone (zone 3).
Recently Maxwell et al. (1989a,b) and previously Van Os-
Corby et al. (1987) have pointed to low oxygen tension being
the likely cause of this retention for MISO. While this may
be so there is also a higher reductase level in zone 3 which
might contribute significantly to the localisation of all three
drugs (Pette & Brandau, 1966; Cobb et al., 1990a).
If it is true that high local reductase activity can outweigh
the ability of oxygen to minimise the reduction of nitro-
imidazole by futile cycling there are clinical implications. For
example, bioreductive cytotoxic drugs may be more effective
in tumours which are not only hypoxic but have high reduc-
tase activity so that cytotoxic metabolites are produced in
both hypoxic and normoxic regions. Also, where nitroimi-
dazoles are used to identify hypoxic cells in pathological
lesions by imaging techniques (e.g. NMR) they may also
concentrate in normal tissues which have high levels of the
appropriate reductase(s) and thus make interpretation more
difficult.
The ARG grain localisation in part reflected the whole
tissue measurements and supported the observation that
some nitroimidazoles are able to form reactive, binding,
metabolites in probably normoxic tissues with high reductase
levels. It is by no means clear whether the high grain density
can be regarded as a measure of cytotoxic potential in tis-
sues. Cytotoxicity in the sebaceous gland group and the
stratified squamous epithelial group would be difficult to
recognise because the cells are normally discarded in a
degenerate form from the skin. The position is different for
the lung and liver where the cells observed to have a high
grain count have a slow turn-over (replacement) rate. It is
interesting to note that these same cells (airway epithelium
and zone 3 of the liver) are damaged by CB 1954, a cytotoxin
and radiosensitiser (Cobb, 1970) which has a similar electron
affinity to MISO (Stratford et al., 1981). It is thought that
the reduction of CB 1954 to a cytotoxin is dependent on the
2 electron transfer reductase DT-diaphorase (Knox et al.,
1988).
In the present work it was noted that both PIMO and
RSU 1069 were associated with melanin containing cells.
This finding confirms previous observations that PIMO was
associated with melanin in the eye in the mouse (Laurent et
al., 1989), with B 16 melanoma cells in the mouse (Walling et
al., 1989) and with xenografted human melanomas in nude
mice (Lespinasse et al., 1989). When Dische (1987) combined
PIMO with radiation in patients with malignant melanoma
he observed a favourable response compared with the ex-
pected response to radiation alone. The connection between
the high grain density over melanin-containing cells in nor-
mal mouse tissue and the apparent improvement in response
to radiation by patients with malignant melanoma is not
clear to us. Many drugs adsorb to, or react with, melanin,
and occasionally this leads to cytotoxic effects (Lindquist et
al., 1973). The presence of melanin in the uveal tract of the
eye in pigmented mice and rats has not been observed to lead
to toxic effect with PIMO or RSU 1069. In man the other
critical tissue containing melanin is the brain (e.g. neuro-
melanin in the substantia nigra); however, melanin is not
seen in the brain of mice or rats.
In conclusion, the accumulation of metabolites in normal
tissues at levels greater than that for tumours is not restricted
to MISO but occurs also in the analogues PIMO and
RSU 1069.918 L.M. COBB et al.
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